At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 24, 2026 at 16:15 ET
Atara Biotherapeutics is holding its 2026 annual meeting to vote on four key proposals: electing two directors, approving executive compensation, increasing shares in its equity incentive plan by 400,000, and ratifying Deloitte & Touche as its auditor. The filing is a routine proxy statement from management.
- Annual meeting to vote on director elections, executive compensation, equity plan increase, and auditor ratification
- Management is soliciting votes for all proposals
- No activist involvement or contested board seats
- Routine annual corporate governance matters
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access